Skip to main content

01.12.2016 | Protocol | Ausgabe 1/2016 Open Access

Systematic Reviews 1/2016

Monoclonal antibody therapy for Kawasaki disease: a protocol for systematic reviews and meta-analysis

Systematic Reviews > Ausgabe 1/2016
Osamu Nomura, Sayaka Fukuda, Erika Ota, Hiroshi Ono, Akira Ishiguro, Tohru Kobayashi
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13643-016-0236-2) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ON conceived and designed the review, completed the PROSPERO registration, and wrote the primary draft. SF was involved in the design of the review and setting the outcomes of review, inclusion, and exclusion criteria. EO provided content expertise in the design and statistical analysis and revised the manuscript. HO and AI contributed to content expertise and feedback and provided important intellectual content. TK conceived and designed the review, provided content expertise in the design and statistical analysis, and revised the manuscript. All authors read and approved the final version of the protocol for submission.



Kawasaki disease (KD) is a form of self-limiting vasculitis that causes coronary artery abnormality in children. Based on reports of elevated plasma level of cytokines such as tumor necrosis factor-α in KD patients, clinical trials of monoclonal antibodies that block cytokine cascades have been conducted. However, the studies have revealed contradictory results. The objective of this study is to examine the effectiveness of treatment with monoclonal antibodies for KD patients.


Relevant randomized controlled trials (RCTs), cluster RCTs, quasi-RCTs, cross-over trials, and any observational studies (e.g., cohort studies, case-control studies, case series, and case reports) will be included to summarize available evidence both qualitatively and quantitatively. Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and ICUSHI will be searched. We will assess coronary artery and treatment outcomes of the interventions. Two authors will independently screen studies for inclusion and consulting with a third author where necessary to resolve discrepancies. The risk of bias of included studies will be assessed using the Cochrane Collaboration risk of bias tool and quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Meta-analysis of the included studies will be conducted using fixed effects or random effects models depending on the degree of between-study heterogeneity. Results will be presented using risk ratios with 95 % confidence interval (CI) for dichotomous outcomes and standardized mean differences with 95 % CI for continuous outcomes.


This systematic review and meta-analysis protocol does not require ethical approval. We will disseminate the findings of this systematic review and meta-analysis via publications in peer-reviewed journals.

Trial registration

PROSPERO CRD42016033079.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

Systematic Reviews 1/2016 Zur Ausgabe